HTA & Payer Evidence Expectations: The US, EU5 & UK Field Guide

Evidence expectations market by market — US payers, NICE, G-BA, HAS and the EU Joint Clinical Assessment
Where payer requirements diverge from regulatory ones, and the study designs that can satisfy both
The timing map: when access evidence has to start to be ready at launch